By viewing this presentation you will learn:
- The role of CDMS in establishing biopharmaceutical standards
- CDMS applications in nucleic acid therapeutics
- The practical impact of CDMS across industry and research
Event Overview
Large molecule biotherapeutics are complex and challenging to characterize using traditional mass spectrometry. In this presentation, brought to you by Waters Corporation, charge detection mass spectrometry (CDMS) innovator Martin Jarrold and experts from US Pharmacopeia (USP) and Waters Corporation, Benjamin Clarke and Rebecca D’Esposito, explore the transformative role of CDMS in the development and quality control of advanced large molecule biotherapeutics. They focus especially on the gene and cell therapy space, such as adeno-associated viruses (AAVs) and nucleic acid-based therapies. Chaired by Martin Jarrold, the session highlights real-world applications of this novel analytical technique in both regulatory and manufacturing contexts.
What You Need to Know
Format: On demand
Duration: 75 minutes
Presenters
 | Martin F. Jarrold, PhD Distinguished Professor, Chemistry, Indiana University; Chief Executive Officer, Megadalton Solutions Martin F. Jarrold is a distinguished chemistry professor at Indiana University and CEO of Megadalton Solutions. Jarrold is a pioneering scientist recognized for revolutionizing charge detection mass spectrometry (CDMS). With a PhD from the University of Warwick and a career spanning roles at AT&T Bell Laboratories and Northwestern University, Jarrold has focused on advancing mass spectrometry techniques to analyze complex, high-mass systems. Widely recognized through numerous awards, including the John B. Fenn Award for Distinguished Contributions in Mass Spectrometry, Jarrold’s research has fundamentally reshaped how large biomolecular assemblies are measured and understood. |
 | Benjamin Clarke, PhD Principal Scientist, US Pharmacopia Ben Clarke develops USP physical reference standards for biologics and ensures their consistent quality and suitability for use. It is his pleasure to work with laboratories across the world to rigorously test USP reference standards and develop new compendial methods. He is the scientific lead for USP’s cell and gene therapy expert volunteers, who are partners in developing standards and quality solutions for advanced therapies. He received his PhD in cell biology from Cornell University and his BS in biochemistry from the Pennsylvania State University. |
 | Rebecca D'Esposito, PhD Senior Scientist, Waters Corporation Rebecca D'Esposito, PhD, is a Senior Scientist at Waters Corporation, where her main area of research is developing cutting-edge applications of Waters CDMS technology. Her current focus includes advancing analytical workflows for gene therapy vectors and other complex biomolecules. Rebecca holds a PhD in Chemistry from the University at Albany, where she explored the structural dynamics of large nucleic acids through ion mobility mass spectrometry and computational modelling. She began her scientific journey with a Bachelor of Science in Forensic Science Technology from Alfred State College. |
